Osimertinib Combined with Apatinib Delays Osimertinib Resistance in T790M Mutated Non-small Cell Lung Cancer
Objective To analyze the clinical effect of Osimertinib combined with Apatinib in delaying Osimertinib resistance in T790M mutated non-small cell lung cancer(NSCLC).Methods A 19 exon-deletion/T790M mutated NSCLC mouse transplanted tumor model was established,and 80 mice were divided into blank control group,Apatinib monotherapy group,Osimertinib monotherapy group and combination group by random number table method,with 20 mice in each group.The tumor growth and the expression of EGFR,VEGF/VEGFR and other signal transduction pathways were compared among the four groups.Results Before administration,there was no significant difference in tumor volume among the four groups(P>0.05).After 30 days of administration,compared with before administration,the tumor volume of Apatinib monotherapy group,Osimertinib monotherapy group and combination group decreased,and was smaller than that of blank control group,while the tumor volume of blank control group increased,P<0.05.Compared with the blank control group,the expression levels of Ki-67,EGFR,VEGFR and mTOR,AKT and ERK proteins in Apatinib monotherapy group,Osimertinib monotherapy group and combination group were significantly decreased.P<0.05.Conclusion Osimertinib combined with Apatinib can significantly inhibit the tumor growth of T790M mutant NSCLC mice,improve the treatment sensitivity of Osimertinib,and delay drug resistance.The mechanism may be related to the inhibition of EGFR and VEGF/VEGFR signaling pathways.
万方数据
维普
